Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01911325
Title Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Buparlisib

Docetaxel

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL

Facility Status City State Zip Country Details
Highlands Oncology Group SC-1 Fayetteville Arkansas 72703 United States Details
H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt Tampa Florida 33612 United States Details
Reliant Medical Group Reliant Medical Group Worcester Massachusetts 01608 United States Details
Virginia Oncology Associates Virginia Oncology Assoc. (2) Norfolk Virginia 23502 United States Details
Novartis Investigative Site Charleroi 6000 Belgium Details
Novartis Investigative Site Mons 7000 Belgium Details
Novartis Investigative Site Creteil 94000 France Details
Novartis Investigative Site Saint Herblain cedex 44805 France Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Mainz 55131 Germany Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Seoul Korea 05505 Korea, Republic of Details
Novartis Investigative Site Seoul Korea 06351 Korea, Republic of Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Stockholm 171 76 Sweden Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field